西格列汀与瑞格列奈治疗初诊2型糖尿病老年患者的效果比较

发布时间：2018-02-25 08:34

本文关键词： 瑞格列奈西格列汀型糖尿病初诊临床效果　出处：《糖尿病新世界》2017年01期 　论文类型：期刊论文

【摘要】：目的比较西格列汀与瑞格列奈治疗初诊2型糖尿病老年患者临床效果。方法选取2016年1—11月在该院治疗的183例2型糖尿病患者进行观察,根据治疗药物的不同分为瑞格列奈组(73例)和西格列汀组(110例),并比较两组患者治疗前后空腹状态下血糖水平(FBG)、餐后血糖水平(PBG)、糖化血红蛋白水平(HbA1C)以及不良反应发生率等。结果治疗前,西格列汀组患者FBG、PBG和HbA1C水平比较差异无统计学意义(P0.05),治疗后两组比较差异有统计学意义(P0.05);西格列汀组患者不良反应发生率明显低于瑞格列奈组,组间比较差异有统计学意义(P0.05)。结论与瑞格列奈治疗比较,西格列汀对2型糖尿病患者具有较好的效果,能明显减少血糖水平,且不良反应较少,该方法值得推广应用。
[Abstract]:Objective to compare the clinical effects of siglitatin and rieglinide in the treatment of newly diagnosed elderly patients with type 2 diabetes. Methods 183 patients with type 2 diabetes treated in our hospital from January to November on 2016 were selected for observation. According to the difference of treatment drugs, the patients were divided into repaglinide group (n = 73) and siglitatin group (n = 110). The fasting blood glucose level (FBGG), postprandial blood glucose level (PBG), glycosylated hemoglobin (HbA1C) and adverse reaction were compared between the two groups before and after treatment. Result before treatment, There was no significant difference in the levels of HbA1C and HbA1C between the two groups, but there was a significant difference between the two groups after treatment (P 0.05), and the incidence of adverse reactions in the siglitatin group was significantly lower than that in the repaglinide group. Conclusion compared with repaglinide treatment, siglitatin has a better effect on type 2 diabetes mellitus patients, can obviously reduce blood glucose level, and has fewer adverse reactions. This method is worth popularizing.
【作者单位】：胶州市中云街道社区卫生服务中心;
【分类号】：R587.1

【相似文献】